Vismodegib (Erivedge)
What is vismodegib?
Vismodegib (Erivedge) is an oral targeted therapy used for certain basal cell carcinomas. It is not traditional chemotherapy. Instead, it works by blocking a pathway that helps drive growth in many basal cell carcinomas.
This medication is generally reserved for situations in which surgery or radiation is not the best fit or when disease is more advanced. It can be administered as a standalone treatment or used to reduce the size of the carcinoma before surgical removal or superficial radiation therapy (SRT).
How does vismodegib work?
Vismodegib blocks the hedgehog signaling pathway. This pathway is important in the development of many basal cell carcinomas. By interrupting that pathway, the medication can help slow or shrink tumor growth.
What are possible side effects of vismodegib?
Possible side effects can include:
Muscle cramps
Hair thinning or hair loss
Changes in taste
Decreased appetite or weight loss
Fatigue
The medication also carries important pregnancy-related warnings because it can cause severe harm to a developing fetus. Careful contraception and handling precautions matter when relevant.
How is vismodegib used?
Vismodegib is taken by mouth on a schedule directed by the treating team. The length of treatment depends on the clinical situation, response, and tolerability rather than a single fixed course.
Because this medication is used in a more specialized setting, treatment planning often involves discussion of alternatives, side-effect management, and careful pregnancy precautions when relevant.